The Effect Observation Of Lobaplatin Combinated Floxuridine/Pirarubicin In Interventional Treatment Of Advanced Unresectable Primary Liver Cancer

Objective:To observe the effect and safety of lobaplatin combinated floxuridine/pirarubicin in transcatheter hepatic arterial chemoembolization of unresectable primary liver cancer.Metheods:Transcatheter hepatic arterial chemoembolization combinated with lobaplatin/floxuridine/pirarubicin were used to treat34unresectable primary liver cancer patients. The DSA/MRI/CT/blood routine examination were used to were evaluated the short term activity and toxicity after4-5weeks,the process was repeated if necessary, the results were observed.Results:Among the34cases,1case (2.9%) showed a complete response,21cases (61.7%) showed a partial response,8cases (23.5%) showed stable diseaseand, and4cases showed progressive disease, with a total effective rate of67.6%. The content of AFP dropped by over50%in20(58.8%) cases. The rate of recovery was hepatalgia (88.2%), ascites (47.1%),appetite(55.9%), engenargy(30.4%).The median follow-up time (MFT) was281days (63-558days),the median pro-gression-free survival was118.5days(95%,CI:88.8-148.2days). Adverse reactions (III-IV grade) were less commom, Only4cases vomiting and2case thrombocytopenia (III grade) were observed.Conclusion:Transcatheter hepatic arterial chemoembolization with Lobaplatin/floxuridine/pirarubicin is an effective and safe treatment for primary liver cancer.